Thermally targeted p21 peptide enhances bortezomib cytotoxicity in androgen-independent prostate cancer cell lines

Anti-Cancer Drugs

Volumn 25, Issue 2, 2014, Pages 189-199

  Mikecin, Ana Matea ^a,b   Walker, Leslie R ^a   Kuna, Marija ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

CDK inhibitors; elastin like polypeptides; proteosomal inhibition; targeted delivery; thermal targeting

Indexed keywords

BORTEZOMIB; POLYPEPTIDE; PROTEIN P21 ELP1 BAC POLYPEPTIDE; UNCLASSIFIED DRUG;

ANDROGEN INDEPENDENT PROSTATE CANCER; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; EXPERIMENTAL HYPERTHERMIA; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MACROMOLECULE; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; HOT TEMPERATURE; HUMANS; MALE; MOLECULAR MIMICRY; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ENGINEERING; PYRAZINES; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 84891840030     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000036     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96
2. Cunha GR, Donjacour A. Stromal-epithelial interactions in normal and abnormal prostatic development. Prog Clin Biol Res 1987; 239:251-272
3. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004; 64:5036-5043
4. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622
5. MacLaren AP, Chapman RS, Wyllie AH, Watson CJ. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 2001; 8:210-218
6. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9:1145-1154
7. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61:3535-3540
8. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T,Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22:2108-2121
9. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005; 5:18
10. Bidwell GL III, Raucher D. Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009; 6:1033-1047
11. Raucher D, Moktan S, Massodi I, Bidwell GL III. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosisinducing peptides. Expert Opin Drug Deliv 2009; 6:1049-1064
12. Bidwell GL III, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005; 4:1076-1085
13. Massodi I, Bidwell GL III, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005; 108:396-408
14. Massodi I, Raucher D. A thermally responsive Tat-elastin-like polypeptide fusion protein induces membrane leakage, apoptosis, and cell death in human breast cancer cells. J Drug Target 2007; 15:611-622
15. Raucher D, Massodi I, Bidwell GL. Thermally targeted delivery of chemotherapeutics and anti-cancer peptides by elastin-like polypeptide. Expert Opin Drug Deliv 2008; 5:353-369
16. Bidwell GL III, Perkins E, Raucher D. A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth. Cancer Lett 2012; 19:136-143
17. Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acidsensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther 2012; 11:1547-1556
18. Koren E, Torchilin VP. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012; 18:385-393
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55
20. Massodi I, Moktan S, Rawat A, Bidwell GL III, Raucher D. Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrier. Int J Cancer 2010; 126:533-544
21. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, O'Connor PM. A p21(Waf1/Cip1)carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res 1999; 59:3480-3488
22. Bidwell GL III, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 2009; 135:2-10
23. Chen J, Jackson PK, Kirschner MW, Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995; 374:386-388
24. Bates S, Ryan KM, Phillips AC, Vousden KH. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. Oncogene 1998; 17:1691-1703
25. Cazzalini O, Perucca P, Riva F, Stivala LA, Bianchi L, Vannini V, et al. p21CDKN1A does not interfere with loading of PCNA at DNA replication sites, but inhibits subsequent binding of DNA polymerase delta at the G1/S phase transition. Cell Cycle 2003; 2:596-603
26. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87:7762-7766
27. Bidwell G III, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006; 71:248-256
28. Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 2008; 9:227-239
29. Roy S, Gu M, Ramasamy K, Singh RP, Agarwal C, Siriwardana S, et al. p21/ Cip1 and p27/Kip1 are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer. Cancer Res 2009; 69:1166-1173
30. Jiang J, Loganathan J, Eliaz I, Terry C, Sandusky GE, Sliva D. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer. Int J Oncol 2012; 40:1339-1344
31. Scott SL, Earle JD, Gumerlock PH. Functional p53 increases prostate cancer cell survival after exposure to fractionated doses of ionizing radiation. Cancer Res 2003; 63:7190-7196
32. Fukuchi K, Hagiwara T, Nakamura K, Ichimura S, Tatsumi K, Gomi K. Identification of the regulatory region required for ubiquitination of the cyclin kinase inhibitor, p21. Biochem Biophys Res Commun 2002; 293:120-125
33. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009; 106:19035-19039
34. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-414